These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 30777785)

  • 41. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.
    Teh LK; Langmia IM; Fazleen Haslinda MH; Ngow HA; Roziah MJ; Harun R; Zakaria ZA; Salleh MZ
    J Clin Pharm Ther; 2012 Apr; 37(2):232-6. PubMed ID: 21507031
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Computer aided warfarin dosing in the Swedish national quality registry AuriculA - Algorithmic suggestions are performing better than manually changed doses.
    Grzymala-Lubanski B; Själander S; Renlund H; Svensson PJ; Själander A
    Thromb Res; 2013 Feb; 131(2):130-4. PubMed ID: 23232091
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of genetic and clinical factors on dose requirements and quality of anticoagulation therapy in Polish patients receiving acenocoumarol: dosing calculation algorithm.
    Wolkanin-Bartnik J; Pogorzelska H; Szperl M; Bartnik A; Koziarek J; Bilinska ZT
    Pharmacogenet Genomics; 2013 Nov; 23(11):611-8. PubMed ID: 24108193
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anticoagulation endpoints with clinical implementation of warfarin pharmacogenetic dosing in a real-world setting: A proposal for a new pharmacogenetic dosing approach.
    Arwood MJ; Deng J; Drozda K; Pugach O; Nutescu EA; Schmidt S; Duarte JD; Cavallari LH
    Clin Pharmacol Ther; 2017 May; 101(5):675-683. PubMed ID: 28032893
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of gene polymorphims on the warfarin treatment at initial stage.
    Liu J; Jiang HH; Wu DK; Zhou YX; Ye HM; Li X; Luo ZY; Guo Z; Zhang YL; Wang YC; Zhang W; Zhou HH; Wang LS
    Pharmacogenomics J; 2017 Jan; 17(1):47-52. PubMed ID: 26644206
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of a pharmacist-managed inpatient anticoagulation service for warfarin initiation and titration.
    Wong YM; Quek YN; Tay JC; Chadachan V; Lee HK
    J Clin Pharm Ther; 2011 Oct; 36(5):585-91. PubMed ID: 21070296
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of an initiation protocol of 4 mg of warfarin for atrial fibrillation in the outpatient setting.
    Sridhar VS; Leung P; Seymour N; Nagge J
    Can Fam Physician; 2014 Nov; 60(11):e535-40. PubMed ID: 25551135
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
    Mega JL; Walker JR; Ruff CT; Vandell AG; Nordio F; Deenadayalu N; Murphy SA; Lee J; Mercuri MF; Giugliano RP; Antman EM; Braunwald E; Sabatine MS
    Lancet; 2015 Jun; 385(9984):2280-7. PubMed ID: 25769357
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms.
    Daly AK
    Arch Toxicol; 2013 Mar; 87(3):407-20. PubMed ID: 23376975
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Implementing Algorithm-Guided Warfarin Dosing in an Ethnically Diverse Patient Population Using Electronic Health Records and Preemptive CYP2C9 and VKORC1 Genetic Testing.
    Obeng AO; Kaszemacher T; Abul-Husn NS; Gottesman O; Vega A; Waite E; Myers K; Cho J; Bottinger EP; Ellis SB; Scott SA
    Clin Pharmacol Ther; 2016 Nov; 100(5):427-430. PubMed ID: 27393744
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacogenetics of warfarin: development of a dosing algorithm for brazilian patients.
    Perini JA; Struchiner CJ; Silva-Assunção E; Santana IS; Rangel F; Ojopi EB; Dias-Neto E; Suarez-Kurtz G
    Clin Pharmacol Ther; 2008 Dec; 84(6):722-8. PubMed ID: 18754001
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Validation and comparison between two warfarin dosing clinical algorithms and warfarin fixed dosing in specialized heart center: cross-sectional study.
    Elnour AA; Ahmed IM; Khalid AK; Elmustafa M
    Pharm Pract (Granada); 2022; 20(3):2722. PubMed ID: 36733524
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CYP2C9*3 polymorphism presenting as lethal subdural hematoma with low-dose warfarin.
    Karnik ND; Sridharan K; Tiwari D; Gupta V
    Indian J Pharmacol; 2014; 46(5):549-50. PubMed ID: 25298588
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Establishment and evaluation of a warfarin-dosing algorithm in Chinese Han population].
    Li C; Dai D; Hu G; Pu C; Cao Y; Cai J
    Zhonghua Yi Xue Za Zhi; 2016 Mar; 96(10):776-80. PubMed ID: 27055637
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Bayesian Estimation Framework for Pharmacogenomics Driven Warfarin Dosing: A Comparative Study.
    Öztaner SM; Temizel TT; Erdem SR; Özer M
    IEEE J Biomed Health Inform; 2015 Sep; 19(5):1724-33. PubMed ID: 25020183
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Genetic warfarin dosing: tables versus algorithms.
    Finkelman BS; Gage BF; Johnson JA; Brensinger CM; Kimmel SE
    J Am Coll Cardiol; 2011 Feb; 57(5):612-8. PubMed ID: 21272753
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of warfarin pharmacogenetic dosing algorithms in a racially diverse large cohort.
    Shin J; Cao D
    Pharmacogenomics; 2011 Jan; 12(1):125-34. PubMed ID: 21174627
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of the predictive abilities of pharmacogenetics-based warfarin dosing algorithms using seven mathematical models in Chinese patients.
    Li X; Liu R; Luo ZY; Yan H; Huang WH; Yin JY; Mao XY; Chen XP; Liu ZQ; Zhou HH; Zhang W
    Pharmacogenomics; 2015; 16(6):583-90. PubMed ID: 25872772
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A review of a priori regression models for warfarin maintenance dose prediction.
    Francis B; Lane S; Pirmohamed M; Jorgensen A
    PLoS One; 2014; 9(12):e114896. PubMed ID: 25501765
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Developing and Validating a Clinical Warfarin Dose-Initiation Model for Black-African Patients in South Africa and Uganda.
    Asiimwe IG; Waitt C; Sekaggya-Wiltshire C; Hutchinson C; Okello E; Zhang EJ; Semakula JR; Mouton JP; Cohen K; Blockman M; Lamorde M; Jorgensen AL; Pirmohamed M
    Clin Pharmacol Ther; 2021 Jun; 109(6):1564-1574. PubMed ID: 33280090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.